Skip to content
DNA concept art

Stilla Technologies Expands U.S. Presence Through Strategic Distribution Relationship with Avantor and Introduces Advanced Content Offerings

• Stilla Technologies expands in the U.S. via a strategic distribution relationship with Avantor, making their digital PCR products more accessible.
• Stilla broadens its offerings to include Cell and Gene Therapy, biopharma quality control, infectious diseases, and applied testing.
• A recent study by Meierrieks et al. revealed that Stilla’s Crystal Digital® PCR with the Ruby Chip is one of the top performers for AAV titration in clarified crude cell lysate.

Paris and Boston – June 6, 2024 – Stilla, a pioneer in the field of genomics and digital PCR, is excited to announce its expansion in the United States via a strategic distribution relationship with Avantor, a global leader in life sciences and advanced technology solutions.

Through this arrangement, Stilla’s comprehensive product range for digital PCR will now be readily accessible to customers across the USA, further enriching Avantor’s genomics core portfolio. This expansion facilitates the distribution of Stilla’s cutting-edge solutions through Avantor’s dedicated Life Sciences specialist team, streamlining access for researchers and clinicians alike.

Kerri McWeeny, GM North America from Stilla, expressed enthusiasm about the relationship, stating, “This collaboration implies a significant milestone for Stilla as we penetrate the USA market. With Avantor’s backing, we are well-positioned to achieve our biopharma, applied testing, and academia objectives while enhancing our applications to better serve our customers.”

Moreover, Stilla proudly announces the expansion of its content offerings to meet the evolving needs of its clientele. With a focus on Cell and Gene Therapy, biopharma quality control, infectious diseases, and applied testing, Stilla aims to provide comprehensive solutions addressing critical challenges in research and diagnostics.

Dr. Afif Abdel Nour, VP of Global Marketing at Stilla, reiterated the company’s commitment to advancing precision medicine through innovation, stating, “At Stilla, we are dedicated to propelling progress in precision medicine through relentless innovation. Our expanded sales force, global presence, and enriched product offerings underscore our unwavering support for our customers and our commitment to advancing the frontiers of molecular diagnostics.”

In related news, a recent study by Meierrieks et al. has unveiled groundbreaking findings in the titration of AAV in clarified crude cell lysate. The study compared various dPCR methods, with Stilla’s Crystal Digital® PCR technology utilizing the Ruby Chip emerging as one of the top performers.

Crystal Digital® PCR showcased exceptional results and minimal coefficient of variation (CV) with just 5µl of total volume and 1 µl of sample. This remarkable efficiency underscores the potential of the Ruby chip for precise and reliable AAV titration, presenting significant advancements in molecular diagnostics.

For further details on the study and its implications please refer to the publication by Meierrieks et al.

About Stilla Technologies
Stilla Technologies is the digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking solutions, include the industry’s first digital PCR systems to feature three, six, and seven fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA. To learn more, visit

About Avantor
Avantor®, a Fortune 500 company, is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit